GLOBAL SACRAL NERVE STIMULATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Sacral Nerve Stimulation Market Size and Forecast – 2025-2032

Global Sacral Nerve Stimulation Market size is expected to reach USD 765.6 Mn by 2032, from USD 502.5 Mn in 2025, exhibiting a compound annual growth rate (CAGR) of 6.2% during the forecast period.

Key Takeaways

• By Product Type, SNS Devices division is predicted to have an astonishing 54.3% of revenue earnings by 2025. They continue to outperform in patient compliance, advanced treatment efficacy and stand as the standard of care in neuromodulation therapy.
• North America is predicted to have an estimated growth of 35.7% market share from their predicted ripe innovation adoption, advanced tech utilization, active reimbursement policies and high-grade healthcare system by 2025.
• Asia Pacific is expected to capture more than 25.2% of the Global Sacral Nerve Stimulation Market Share in the region by 2025, making it the second-largest market. The additional investment and developed understanding in spinal neuromodulation devices along with pelvic floor disorder awareness is what is expected to fuel the growth.
• The rest of Europe is predicted to grow most rapidly capturing 19% of the market share by 2025. The emerging metrics of population suffering with fecal incontinence alongside growing efforts to reduce the use of invasive treatments in the region is propelling the growth.

Market Overview

The sacral nerve stimulation (SNS) procedure is minimally invasive in nature since it involves treating disorders of the bladder, bowels, and pelvic floor by placing a small medical device known as an implantable neurostimulator. A small neurostimulator device is implanted near the sacral nerves, which control important pelvic region functions. The device alleviates symptoms like urinary and fecal incontinence, and retention by providing mild electric pulses that restore communication between the pelvic organs and the brain. SNS is more frequently selected by patients because of its lasting effectiveness, customizable parameters, and its ability to enhance quality of life. For example, Medtronic’s InterStim system has shown positive outcomes in patients with overactive bladder, offering long-term relief and improved quality of life through customizable and reversible stimulation therapy.

Current Events and Its Impact on the Global Sacral Nerve Stimulation Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Global Sacral Nerve Stimulation Market Insights, By Type – Implantable SNS Systems Secure Technological Leadership

By Type, implantable sacral nerve stimulation (SNS) systems, are expected to capture the majority Global Sacral Nerve Stimulation Market Demand share of 54.3% by 2025 due to its therapeutic convenience as well as its long-term effectiveness in managing chronic disorders such as overactive bladder (OAB) and fecal incontinence. X’s InterStim rechargeable battery powered implantable systems are less invasive than external SNS devices, and also offer battery life of up to 15 years. This reduces the need for replacement on frequent basis. This markedly improves patient comfort and significantly cuts healthcare costs in the long run.

Closed loop stimulation as well as innovative technology like MRI compatible devices boost the region even further. For example, the remote programming and full body MRI compatibility offered by the Axonics R20 makes it clinically approved by FDA in 2023. Also in 2024, studies published in Neurourology and Urodynamics concluded patients using implantable SNS devices to alleviate OAB symptoms spent less than patients using pharmacological alternatives.

Global Sacral Nerve Stimulation Market Insights, By Application – Urinary Incontinence Leads Therapeutic Adoption

By Application, urinary incontinence is projected to be the leading segment in Global Sacral Nerve Stimulation Market Forecast by 2025, accounting for more than 50% of total SNS procedures globally. This prevalence is related to the increasing occurrence of overactive bladder and urge incontinence, particularly in the elderly populations of North America, Europe, and East Asia. The International Continence Society estimates that the number of people affected by urinary incontinence globally has reached around 400 million as of 2024, with projections indicating significant increase by 2030.

SNS therapy offers a non-pharmacological solution for patients who do not respond to behavioral or medication therapy. According to results from the RELAX-OAB trial completed in 2023, more than 72 % of patients undergoing SNS for urinary incontinence suffered at least a 50 % reduction in symptoms within six months, compared to 39% of the participants treated with medication.

Fecal incontinence, on the other hand, remains the second larger application with increased clinical understanding and specific SNS treatment. The American Society of Colon and Rectal Surgeons (ASCRS) now consider SNS therapy as one of the initial treatment options for moderate to severe fecal incontinence, particularly for females with pelvic floor dysfunction. Furthermore, chronic pelvic pain and neurogenic bladder are becoming niche target areas with an expanding volume of clinical trials investigating the use of SNS.

Global Sacral Nerve Stimulation Market Insights, By End User – Hospitals Remain Primary Centers for Device-Based Intervention

By End User, hospitals are set to retain the largest share of the Global Sacral Nerve Stimulation Market Growth in 2025, owing to the complexity of the implantation procedure, need for multidisciplinary surgical teams, and advanced imaging and intraoperative monitoring capabilities available in these settings. The American Urological Associations recommends SNS procedures be performed at certified centers in order to guarantee safety, proper device tuning, and evaluation during the procedure.

According to the Global Continence Care Network (GCCN), more than 68% of all SNS implants were performed in tertiary care hospitals as of 2024. These hospitals have advanced departments of urology and colorectal surgery which aid in cumulative and longitudinal care customization and management.

Trial stimulation procedures are gaining popularity in the United States and Western Europe, particularly within Ambulatory Surgical Centers (ASCs), because of quicker completion times and lower operational expenses. As an example, the use of Axonics’ trial leads in outpatient settings has resulted in a cost reduction of almost 30% before implantation. On the contrary, the fully implanted systems are still predominantly performed in hospitals due to anesthesia, postoperative monitoring, and recovery needs.

With the development of app-connected SNS systems, specialty clinics and home healthcare centers are starting to serve as platforms for remote monitoring and recharge management. However, their contributions are limited in this area as they primarily serve as complements to the main care provided at hospitals.

Regional Insights

To learn more about this report, Download Free Sample

North America Sacral Nerve Stimulation Market Analysis and Trends

North America is anticipated to maintain its leadership in the Global Sacral Nerve Stimulation Market Outlook, expected to capture over 35.7% of the market share in 2025. This dominance is driven by the robust healthcare infrastructure, high levels of healthcare spending, and a growing prevalence of conditions such as overactive bladder (OAB) and fecal incontinence (FI).

United States Sacral Nerve Stimulation Market Analysis and Trends

The United States is expected to hold the largest share of the North American SNS market. With leading players like Medtronic, Boston Scientific, and Axonics dominating the market, the U.S. continues to be the center for innovation in sacral neuromodulation devices. The market's growth is further fueled by widespread insurance coverage, including Medicare, which makes SNS treatment more accessible to a broad patient base. Additionally, the U.S. is a leader in regulatory approvals, with the FDA's recent approval of next-generation devices, such as Axonics' rechargeable sacral neuromodulation system, bolstering the market's growth trajectory.

Asia Pacific Sacral Nerve Stimulation Market Analysis and Trends

Asia Pacific is poised to be the second-largest and the fastest-growing Global Sacral Nerve Stimulation Market Value, anticipated to account for over 25.2% of the global market share by 2025. The rapid expansion of healthcare infrastructure and a growing middle class in countries like China and India are significant drivers of SNS adoption.

Sacral Nerve Stimulation Market Dominating Countries

China Sacral Nerve Stimulation Market Analysis and Trends

Due to the country’s aging population alongside the increase in healthcare needs, China remains a substantial participant in the Asia Pacific Global Sacral Nerve Stimulation Market Analysis. China is undergoing significant healthcare reforms, which includes increased SNS treatment access. In addition to this, the growing incidence of urinary and fecal incontinence due to aging and chronic diseases also increases the need for neuromodulation therapies. The country is experiencing rapid growth in this sector due to its large population, and immense development of the country’s healthcare infrastructural facilities.

India Sacral Nerve Stimulation Market Analysis and Trends

As a result of the increased awareness around healthcare and need for economical treatment services, India offers the most notable SNS market expansion potential. Urban and rural populations are gaining access to SG and SNS treatment as the country’s healthcare infrastructural facilities continue to develop. The large diabetic and geriatric populations in the country further intensify the need for effective treatment for OAB and FI, thereby making SNS devices a feasible solution. Additionally, the increasing number of hospitals and medical centers in Tier Two and Tier Three cities is likely to enhance the adoption of SNS.

Europe Global Sacral Nerve Stimulation Market Analysis and Trends

Europe is expected to witness steady growth in the Sacral Nerve Stimulation Market, holding about 19% of the Global Sacral Nerve Stimulation Market Trends share in 2025. The growth is largely driven by the rising incidence of fecal and urinary incontinence, particularly among the aging population in many European countries.

Germany Sacral Nerve Stimulation Market Analysis and Trends

Germany possesses SNS as one of the largest SNS markets in Europe because of its developed healthcare system and strong reimbursement policies. Due to the considerable elderly population, Germany SNS adoption is increasing because of high healthcare spending, particularly in hospitals and urology clinics. The growth of SNS treatments is further propelled by the presence of major medical device companies and strong healthcare regulatory frameworks.

United Kingdom Sacral Nerve Stimulation Market Analysis and Trends

The SNS market in the United Kingdom is expected to experience moderate growth due to the increasing prevalence of OAB and FI among the geriatric population. SNS treatment accessibility gaps are mitigated by the National Health Service (NHS) as several guidelines provide for the use of neuromodulation as a treatment for refractory incontinence. Awareness of the conditions combined with the advancements of SNS technology is expected to bolster market growth.

France Sacral Nerve Stimulation Market Analysis and Trends

France is expected to experience the steadiest growth in the SNS market as focus on treatment of incontinence becomes more common among the aging population. The French healthcare system is responsive towards the adoption of new medical technologies such as SNS, with a significant number of patients and insured persons using stimulators covered with health insurance. France’s healthcare policies aimed at the improving the quality of life for the elderly citizens and those suffering from disabilities and chronic diseases further stands to solidify this perception.

Global Sacral Nerve Stimulation Market - Recent Developments

• November 2023 – Medtronic plc brought its InterStim X™ system to India, making it the first recharge-free device SNM system that is also MRI-compatible, has a battery life of over fifteen years, and enables personalized therapy SNM.
• January 2024 – Boston Scientific disclosed plans to purchase Axonics, Inc. for around USD 3.4 billion, intending to strengthen its foothold in urology and pelvic health through the Innovative SNM technologies developed by Axonics.

Market Report Scope

Global Sacral Nerve Stimulation Market - Drivers

• Rising geriatric population: Increasing geriatric population globally is expected to propel the market growth over the forecast period. For instance, on October 1, 2025, according to the data published by the World Health Organization, in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years. Moreover, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%.
• Growing prevalence of urinary incontinence: Increasing prevalence of urinary incontinence globally will aid in the market growth over the forecast period.

Global Sacral Nerve Stimulation Market - Trends

• Wireless and battery less sacral nerve stimulation systems: The advent of wireless and battery less sacral nerve stimulation systems is expected to witness significant impact the global sacral nerve stimulation market in the near future. Sacral nerve stimulation is commonly used to treat overactive bladder, urinary retention, and fecal incontinence. The traditional systems require battery replacements every few years which involves additional surgeries. This increases the costs burden and risk to patients over the long run of treatment.

Global Sacral Nerve Stimulation Market – Opportunities

Development of novel stimulation systems: The stimulation techniques that serve to activate sacral nerves can be greatly advanced through novel systems of stimulation. Due to the progress currently undertaken in neuro technology, researchers are trying to design less invasive methods of stimulation that are more effective and economical in treating the pathological conditions. Among the other new methods are being considered stimulation implants, micro-scaled electrode arrays, and individualized stimulation protocols developed by AI and Machine Learning algorithms.

Reimbursement Scenario

 Reimbursement for sacral nerve stimulation (SNS) varies globally, with the U.S. offering the most structured framework through defined CPT and ICD-10-CM codes. Medicare and private insurers typically cover SNS for patients with refractory urinary or fecal incontinence after conservative treatments fail. Key CPT codes include 64561 (percutaneous implantation), 64590 (pulse generator insertion), and 95971/95972 (device programming). Medicare covers 80% of costs under Part B, with average payments around $18,000 for facilities and $2,500 for surgeons. Private insurers generally mirror Medicare but may impose stricter authorization criteria.

Analyst Viewpoints

• Technological progress within implantable devices is enhancing patient outcomes through less invasive procedures and better battery life, which is propelling growth in the Global Sacral Nerve Stimulation (SNS) Market.
• Overactive bladder and fecal incontinence are just two examples of the urological and gastrointestinal disorders that are increasing in SNS’s availability as a non-invasive pharmacological long-term treatment option.
• This is expanding the scope of the market due to growing awareness of the use of neuromodulation for chronic pelvic floor disorders among clinicians and patients alike.
• On the other hand, the absence of reimbursement along with lack of surgical skill cuts off access, especially in low and middle- income countries. This creates a financial barrier due to the expensive devices and procedures.
• Emerging economies are also hindered by the complex regulations and ever-changing reimbursement policies resulting in slower growth in these markets.
• There are opportunities available with the widening of SNS applications to include chronic pelvic pain and sexual dysfunction as this provides new patient populations and diversified clinical use.
• The expansion of spending on healthcare and, to some extent, awareness coupled with better infrastructure will heavily influence the growth of Asia-Pacific’s economy. North America continues to lead the market, as they have supportive reimbursement models and quickly adopt new technologies.
• To resolve the issue of affordability and to accelerate adoption in new untapped areas, strategic partnerships between global SNS producers and local SNS distributors will be fundamental.
• Continued investment into remote monitoring systems and the development of devices centered around the patient will increase the chances of the patients using the devices, thus enhancing competitiveness in the market.

Business Development Activities by the Market Players

In April 2023, Axonics, Inc.,a global medical technology company that develops and commercialize novel products for the treatment of bladder and bowel dysfunction, announced the acquisition of a lead placement solution from Radian, LLC. that complements Axonics Inc.s’ existing sacral neuromodulation (SNM) offering.

Market Segmentation

• Global Sacral Nerve Stimulation Market, By Product Type
• Implantable SNS Devices
• External SNS Devices
• Accessories
• Global Sacral Nerve Stimulation Market, By Application
• Urinary and Fecal Incontinence
• Chronic Pain
• Others
• Global Sacral Nerve Stimulation Market, By End User
• Hospital
• Clinics
• Ambulatory Surgery Centers
• Global Sacral Nerve Stimulation Market, By Region
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Global Sacral Nerve Stimulation Market:
• Medtronic plc.
• Boston Scientific Corporation
• Nevro Corp
• StimWave Technologies Inc.
• Axonics, Inc.
• Synapse Biomedical
• Uroplasty
• Jude Medical
• Cogentix Medical
• Others

Sources

Primary Research Interviews

• Medtronic representatives
• Laborie pelvic health experts
• NeuroPace, Inc. neuromodulation specialists
• Nuvectra product development professionals
• Others

Databases

• Factiva (Device Market Trends)
• National Library of Medicine (Clinical Insights)
• Others

Magazines

• Medical Device Network
• Neurology Today
• Healthcare Business Review
• MedTech Outlook
• Others

Journals

• Neuromodulation: Journal of the International Neuromodulation Society
• Journal of Urology
• Pelviperineology
• Others

Newspapers

• The Wall Street Journal (Healthcare Innovations)
• Financial Times (Global Market Trends)
• The Economic Times (Regional Healthcare Developments)
• Others

Associations

• International Continence Society
• American Urological Association
• European Association of Urology
• Others

Public Domain Sources

• National Institutes of Health (NIH)
• U.S. Food and Drug Administration (FDA)
• World Health Organization (WHO)
• Grand View Research
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years

Definition: Sacral nerve stimulation (SNS) is a minimally invasive procedure that involves placing a small medical device called an implantable neurostimulator to treat bladder, bowel, and pelvic floor disorders.